The Polymyalgia Rheumatica Drugs Market is driven by rising geriatric population
The Polymyalgia rheumatica drugs market involves medications that are used for treating polymyalgia rheumatica, an inflammatory disorder commonly seen in elderly adults. Some of the key drugs in this market include corticosteroids such as prednisone and glucocorticoids which help reduce swelling and pain. Biologics inhibiting specific pro-inflammatory pathways are also becoming increasingly important in managing refractory cases.
The polymyalgia rheumatica drugs market is estimated to be valued at USD 266 Mn in 2024 and is expected to reach USD 662 Mn by 2031, growing at a compound annual growth rate (CAGR) of 13.9% from 2024 to 2031.
The growing geriatric population prone to age-related disorders is a key factor driving the demand for Polymyalgia Rheumatica Drugs Market. According to estimates, over 1.5 billion people will be aged over 65 by 2050. This elderly segment is more likely to suffer from conditions like polymyalgia rheumatica requiring long-term management.
Get more insights on: Polymyalgia Rheumatica Drugs Market
Get this Report in Japanese Language: リウマチ性多発筋痛症治療薬市場
Get this Report in Korean Language: 다발성 근육통 류마티스 약물 시장
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian